Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.32 USD
-0.02 (-1.13%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.32 +0.01 (0.38%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Earnings News For SPRO
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates
-
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to Decline
-
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
-
Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Lags Revenue Estimates
-
Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for
-
Spero Therapeutics Inc (SPRO) Reports Q1 Loss, Misses Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
-
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to Decline
-
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
-
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates